Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study

Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) trials.Methods Eligible patients completing the 24-week DARWIN 1 (filgotinib plus methotrexate) and DARW...

Full description

Saved in:
Bibliographic Details
Main Authors: Arthur Kavanaugh, Paul Emery, René Westhovens, Mark C Genovese, Kevin L Winthrop, Rieke Alten, Dick de Vries, Lorenzo Dagna, Patrick Verschueren, Maria Greenwald, Regina Cseuz, Robin Besuyen, Vikas Modgill, Ly Huong Le
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/11/1/e004857.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items